Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — H1 FY22 Earnings Presentation
14 slides from Atomo Diagnostics's earnings presentation, Feb 22, 2022
Slide 1: Half Year Results Presentation
Atomo Diagnostics Limited Authorised by John Kelly, Managing Director 701 – 703 Parramatta Road Leichhardt NSW 2040 Australia Half Year Results Presentation 22 February 2022 ATOMO ATOMO DIAGNOSTICS DIAGNOSTICS LIMITED|| (ASX: LIMITED (ASX: AT1) AT1)
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on communications transmitted or otherwise made available to the recipient in information available as at the date of this presentation. The information in this connection with the opportunity outlined in thi
Slide 3: Introduction
INTRODUCTION Atomo Diagnostics Limited (ASX: AT1) is an innovative medical device diagnostics company supplying unique, integrated rapid diagnostic test (RDT) devices and finished point-of-care rapid tests to the global market Headquartered in Australia with international operations, Atomo develops,
Slide 4: H1 FY22 – Profit and Loss
H1 FY22 – PROFIT AND LOSS • Overall gross revenue from customers increased by 53% to $7.0m (vs PCP H1 FY21), driven by: • Total sales from ordinary operating activities was $5.34m during the period. In • strong demand for COVID-19 point of care tests addition, revenue of $1.65m was received from lic
Slide 5: H1 FY22 – Balance Sheet
H1 FY22 – BALANCE SHEET • Trade receivables were lower at 31 December 2021, as the proportion of sales related to COVID-19 rapid antigen testing in Australia increased, where customers are on shorter payment terms when compared with OEM and HIV customers • Total R&D spend for H1 FY22 of $1.72m: • $7
Slide 6: H1 FY22 – Cashflow Activities
H1 FY22 – CASHFLOW ACTIVITIES • Cash receipts of $7.73m for the half, underpinned by demand for COVID-19 rapid antigen test sales and growth in HIV sales • R&D Tax rebate of $1.8m received • Cash outflows predominantly consisting of: • payments for stock to meet demand from customers in COVID-19 • r
Slide 7: A Permanently Changed Diagnostic Market
A PERMANENTLY CHANGED DIAGNOSTIC MARKET Tailwinds and headwinds HIV Near Term • Immediate revenue growth opportunities in COVID rapid testing resulting from an unprecedented global pandemic • A contraction of IVD industry new product Medium Term commercialisation pipelines and resulting impact to At
Slide 8: Atomo's Core Capabilities
ATOMO’S CORE CAPABILITIES The intersection between Medical Devices & Diagnostics Less IP Intensive IP Intensive More sales focused Atomo DNA Core Functionality Devices Finished Products Customer Delivery Point-of-Care Self Testing • Blood collection • Galileo • HIV • Atomo Direct to • Saliva & swab
Slide 9: Atomo's Operational Footprint
ATOMO’S OPERATIONAL FOOTPRINT Europe Asia North America • HIV ST, Blood based • Cassette moulding and assembly pregnancy and FebriDx all (Current Annual Manufacturing • Biggest partnership CE Marked Capacity: ~20M) opportunities • OEM partners: NG Biotech • Seeking China market entry partner • Rapid
Slide 10: Atomo's Strategic Focus
ATOMO’S STRATEGIC FOCUS HIV Core Capabilities Innovation, Co-development & Commercialisation (device design, usability, manufacturability, IP, regulatory, co-commercialisation) Markets Infectious Rapid Test Consumer Health Diseases Testing Devices & Wellness (HIV, COVID, Others) (devices, components
Slide 11: A Growing Infectious Disease Business
Market A GROWING INFECTIOUS DISEASE BUSINESS HIV HIV OTHER TESTS COVID-19 Antigen - Australia Atomo has an opportunity to continue to meet demand for COVID-19 testing in Australian and NZ markets OEM Devices for Respiratory applications Atomo’s swab device improves usability and performance in swab
Slide 12: Rapid Testing in Australia
Market RAPID TESTING IN AUSTRALIA HIV COVID-19 TESTING SUMMARY • Australia demonstrated significant demand for rapid COVID-19 tests in late 2021 after roll-out delays due to resistant public health policy • Atomo sold 420k rapid COVID tests during H1 FY22, with product sales in January outstripping
Slide 13: OEM Market – Atomo Rapid Test Devices: Unique Solutions
OEM MARKET – ATOMO RAPID TEST DEVICES: UNIQUE SOLUTIONS Accelerate roll-out of current solutions with existing Leverage existing approvals, with potential for partners to upgrade existing blood platforms products to an Atomo cassette or commercialise their new tests using Atomo cassettes and compone
Slide 14: Clinic at Home – The Next Healthcare Frontier
CLINIC AT HOME – THE NEXT HEALTHCARE FRONTIER two thirds of all clinical decisions are based on a diagnostic test Strategic Opportunity / home testing market: Rapidly emerging new market for eHealth enabled healthcare in the home, cannibalising lab/clinic-based models as well as challenging traditio